quinazolines has been researched along with Graft vs Host Disease in 16 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (6.25) | 18.7374 |
| 1990's | 3 (18.75) | 18.2507 |
| 2000's | 4 (25.00) | 29.6817 |
| 2010's | 3 (18.75) | 24.3611 |
| 2020's | 5 (31.25) | 2.80 |
| Authors | Studies |
|---|---|
| Assanelli, AA; Bernardi, M; Bruno, A; Carrabba, MG; Ciceri, F; Clerici, D; Corti, C; Farina, F; Giglio, F; Greco, R; Guggiari, E; Lazzari, L; Lorentino, F; Lunghi, F; Lupo-Stanghellini, MT; Marcatti, M; Marktel, S; Mastaglio, S; Peccatori, J; Piemontese, S; Ruggeri, A; Xue, E | 1 |
| Babushok, D; Carulli, A; Frey, NV; Freyer, CW; Ganetsky, A; Gier, S; Gill, SI; Hexner, EO; Loren, AW; Luger, SM; Mangan, JK; Martin, ME; McCurdy, SR; Perl, AE; Porter, DL; Pratz, K; Schuster, M; Smith, J; Stadtmauer, EA; Timlin, C | 1 |
| Hosoi, H; Murata, S; Mushino, T; Nishikawa, A; Sonoki, T | 1 |
| Abramova, R; Assal, A; Bansal, R; Gordillo, CA; Mapara, MY; Pereira, MR; Reshef, R | 1 |
| Cho, C; DeRespiris, L; Devlin, SM; Figgins, B; Flynn, J; Giralt, SA; Griffin, M; Jakubowski, AA; Lau, C; Lin, A; Papadopoulos, EB; Perales, MA; Proli, A; Seo, SK; Shaffer, B; Tamari, R | 1 |
| Benesch, M; Donnerer, J; Kubesch, K; Lackner, H; Schwinger, W; Sperl, D; Strenger, V; Zach, K | 1 |
| Eizik, O; Gelfand, Y; Morecki, S; Sagiv, I; Shabat, Y; Slavin, S; Yacovlev, E | 1 |
| Altman, A; Kong, KF | 1 |
| Cetkovic-Cvrlje, M; Liu, XP; Roers, BA; Schonhoff, D; Uckun, FM; Waurzyniak, B | 1 |
| Nagler, A; Pines, M; Snyder, D; Yarkoni, S | 1 |
| Cetkovic-Cvrlje, M; Uckun, FM | 1 |
| Knopov, V; Levi-Schaffer, F; Nagler, A; Pines, M; Slavin, S | 1 |
| Genina, O; Halevy, O; Levi-Schaffer, F; Nagler, A; Pines, M | 1 |
| Nagler, A; Pines, M | 1 |
| Cetkovic-Cvrlje, M; Liu, XP; Roers, BA; Uckun, FM; Waurzyniak, B | 1 |
| Appelbaum, FR; Deeg, HJ; Graham, TC; Raff, RF; Sandmaier, B; Schuening, F; Storb, R | 1 |
1 review(s) available for quinazolines and Graft vs Host Disease
| Article | Year |
|---|---|
Halofuginone to treat fibrosis in chronic graft-versus-host disease and scleroderma.
Topics: Administration, Cutaneous; Animals; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Collagen Type I; Fibrosis; Graft vs Host Disease; Humans; Mice; Piperidines; Protein Synthesis Inhibitors; Quinazolines; Quinazolinones; Scleroderma, Systemic | 2003 |
15 other study(ies) available for quinazolines and Graft vs Host Disease
| Article | Year |
|---|---|
Letermovir reduces chronic GVHD risk in calcineurin inhibitor-free GVHD prophylaxis after hematopoietic cell transplantation.
Topics: Acetates; Calcineurin Inhibitors; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Quinazolines | 2022 |
Letermovir vs. high-dose valacyclovir for cytomegalovirus prophylaxis following haploidentical or mismatched unrelated donor allogeneic hematopoietic cell transplantation receiving post-transplant cyclophosphamide.
Topics: Acetates; Adult; Cyclophosphamide; Cytomegalovirus; Cytomegalovirus Infections; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Quinazolines; Retrospective Studies; Unrelated Donors; Valacyclovir | 2022 |
Eosinophilia during letermovir treatment after allogeneic hematopoietic stem cell transplantation.
Topics: Acetates; Adult; Aged; Allografts; Antiviral Agents; Case-Control Studies; Cytomegalovirus Infections; Eosinophilia; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Middle Aged; Quinazolines; Transplantation Conditioning | 2020 |
Extended letermovir administration, beyond day 100, is effective for CMV prophylaxis in patients with graft versus host disease.
Topics: Acetates; Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infections; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Quinazolines; Retrospective Studies | 2021 |
Letermovir for Prevention of Cytomegalovirus Reactivation in Haploidentical and Mismatched Adult Donor Allogeneic Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide for Graft-versus-Host Disease Prophylaxis.
Topics: Acetates; Adult; Cyclophosphamide; Cytomegalovirus; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Quinazolines | 2021 |
Letermovir in paediatric HSCT recipients.
Topics: Acetates; Antiviral Agents; Child; Cytomegalovirus Infections; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Liver Diseases; Quinazolines; Transplant Recipients | 2019 |
Selective elimination of alloreactivity in vitro and in vivo while sparing other T-cell-mediated immune responses.
Topics: Animals; Disease Models, Animal; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunity, Cellular; Immunotherapy; Isoantigens; Mice; Mice, Inbred BALB C; Quinazolines; T-Lymphocytes; Transplantation, Homologous | 2012 |
PKCθ: a new target for selective immunosuppression.
Topics: Animals; Graft Rejection; Graft vs Host Disease; Humans; Immunosuppression Therapy; Isoenzymes; Mice; Mice, Knockout; Molecular Targeted Therapy; NF-kappa B; Protein Kinase C; Protein Kinase C-theta; Protein Kinase Inhibitors; Psoriasis; Pyrroles; Quinazolines; Signal Transduction; T-Lymphocytes | 2012 |
Treatment of post-bone marrow transplant acute graft-versus-host disease with a rationally designed JAK3 inhibitor.
Topics: Acute Disease; Animals; Body Weight; Bone Marrow Transplantation; Drug Design; Drug Evaluation, Preclinical; Enzyme Inhibitors; Graft vs Host Disease; Histocompatibility; Janus Kinase 3; Mice; Mice, Inbred BALB C; Mice, Knockout; Protein-Tyrosine Kinases; Quinazolines; Survival Analysis; Transplantation, Homologous | 2002 |
Dual targeting of Bruton's tyrosine kinase and Janus kinase 3 with rationally designed inhibitors prevents graft-versus-host disease (GVHD) in a murine allogeneic bone marrow transplantation model.
Topics: Acute Disease; Agammaglobulinaemia Tyrosine Kinase; Amides; Animals; Bone Marrow Transplantation; Drug Therapy, Combination; Enzyme Inhibitors; Graft vs Host Disease; Immunosuppressive Agents; Janus Kinase 3; Male; Methotrexate; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Nitriles; Protein-Tyrosine Kinases; Quinazolines; Survival Rate; Treatment Outcome | 2004 |
Inhibition of collagen synthesis and changes in skin morphology in murine graft-versus-host disease and tight skin mice: effect of halofuginone.
Topics: Animals; Collagen; Disease Models, Animal; Fibrosis; Graft vs Host Disease; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Mutant Strains; Osmolar Concentration; Piperidines; Quinazolines; Quinazolinones; Scleroderma, Localized; Skin | 1996 |
Inhibition of collagen type I synthesis by skin fibroblasts of graft versus host disease and scleroderma patients: effect of halofuginone.
Topics: Adult; Coccidiostats; Collagen; Dose-Response Relationship, Drug; Female; Fibroblasts; Graft vs Host Disease; Humans; Middle Aged; Piperidines; Quinazolines; Quinazolinones; Time Factors | 1996 |
Topical treatment of cutaneous chronic graft versus host disease with halofuginone: a novel inhibitor of collagen type I synthesis.
Topics: Administration, Topical; Adult; Animals; Collagen; Gene Expression; Graft vs Host Disease; Humans; Male; Neck; Piperidines; Protein Synthesis Inhibitors; Quinazolines; Quinazolinones; Rabbits; Range of Motion, Articular; Sclerosis; Skin; Skin Transplantation | 1999 |
Targeting Janus kinase 3 to attenuate the severity of acute graft-versus-host disease across the major histocompatibility barrier in mice.
Topics: Acute Disease; Animals; Bone Marrow Transplantation; Cell Transplantation; Drug Evaluation, Preclinical; Drug Therapy, Combination; Enzyme Inhibitors; Graft vs Host Disease; H-2 Antigens; Immunosuppressive Agents; Janus Kinase 3; Lymphocyte Activation; Lymphocyte Culture Test, Mixed; Male; Methotrexate; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Phytohemagglutinins; Protein-Tyrosine Kinases; Quinazolines; Radiation Chimera; Signal Transduction; Spleen; T-Lymphocytes, Cytotoxic; Whole-Body Irradiation | 2001 |
Use of trimetrexate for the prevention of graft-versus-host disease.
Topics: Animals; Antineoplastic Agents; Child; Cyclosporins; Dogs; Drug Combinations; Folic Acid Antagonists; Graft Rejection; Graft vs Host Disease; Humans; Immunosuppressive Agents; Quinazolines; Trimetrexate | 1989 |